Overview


According to FutureWise analysis, the market for Hepatology is expected to grow with a CAGR of 12.10% over the forecast period 2023-2031, and reach a market value of US$ 35.85 billion by 2031.

Hepatology is an area of medicine that focuses on the analysis, diagnosis, and treatment of diseases related to the liver, gallbladder, biliary tree, and pancreas. It is a specialized field within gastroenterology, which deals with diseases of the digestive system. Hepatologists are medical doctors who have undergone additional training and education in the field of hepatology. Hepatologists work closely with other medical specialists, such as gastroenterologists, surgeons, radiologists, and oncologists, to provide comprehensive care for patients with liver and related conditions. They may also be involved in liver transplantation, a life-saving procedure for individuals with end-stage liver disease.

The some of the most common liver diseases and conditions categorized by disease types are viral hepatitis, non-alcoholic fatty liver disease, autoimmune disease, and genetic liver disorder. Viral hepatitis includes infections caused by hepatitis viruses (such as Hepatitis A, B, C, etc.), which can lead to liver inflammation and, if not managed properly, can result in chronic liver disease. Non-alcoholic fatty liver disease is a condition indicated by the aggregation of fat in the liver cells, not caused by alcohol. It's often associated with obesity, diabetes, and metabolic syndrome. Moreover, in liver cancer or hepatocellular carcinoma, hepatologists are involved in the diagnosis and management of primary liver cancers. Autoimmune liver diseases are conditions where the immune system mistakenly targets and damages the liver, such as primary biliary cirrhosis, autoimmune hepatitis, and primary sclerosing cholangitis. Genetic disorders are conditions like hemochromatosis, Wilson's disease and alpha-1 antitrypsin deficiency are caused by genetic mutations affecting liver function.

FutureWise Market Research has published a report that provides an insightful analysis hepatology market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts hepatology market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Astellas Pharma Inc.
  • Merck & Co. Inc.
  • Abbott Laboratories
  • Bristol- Myers Squibb
  • AbbVie Inc.
  • Emergent BioSolutions Inc.
  • F. Hoffmann- La Roche AG
  • Eli Lilly and Company
  • Viatris Inc.
  • Gilead Sciences, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Hepatology Market:

  • In October 2022, Salix Pharmaceuticals released the Salix Liver Health Annual Trends Report, which encompasses the latest data on treating chronic liver disease (CLD), particularly in the field of hepatology. This report highlights an ongoing increase in hospital admissions and mortality rates attributed to CLD and cirrhosis. It also underscores crucial insights that could lead to early diagnosis and management of CLD, cirrhosis, and its associated complications.
  • In June 2023, Zydus Lifesciences initiated a Phase IV real-world data registry trial to assess the benefits of Saroglitazar Magnesium in individuals with non-alcoholic fatty liver disease (NAFLD) and comorbidities, focusing on hepatology. This "Phase IV evidence-XI" study will encompass approximately 1,500 males and female NAFLD patients with comorbidities such as obesity, type 2 diabetes mellitus, metabolic syndrome, and dyslipidemia, with 200 patients falling into each category.

The rising incidence of liver-related disorders, including hepatitis, fatty liver disease, and cirrhosis, serves as a substantial driver for the hepatology market. This surge may be attributed to a combination of factors: escalating levels of alcohol consumption, a widespread prevalence of obesity, and the persistence of viral infections. These elements collectively contribute to the growing burden of liver diseases, necessitating an increased focus on advanced diagnostic techniques, therapeutic interventions, and comprehensive care strategies within the hepatology market. Furthermore, technological advancement in diagnostic, advanced imaging techniques, and innovative therapeutic interventions have significantly enhanced the precision and effectiveness of liver disease detection and treatment. This progress not only boosts confidence in patients seeking advanced hepatological care but also encourages healthcare providers to employ cutting-edge approaches in managing liver-related conditions. Moreover, the increasing aging population is anticipated to propel the growth of the hepatology market. As individuals grow older, they are more exposed to various liver-related diseases, including fatty liver disease, cirrhosis, and hepatocellular carcinoma. This vulnerability arises from the cumulative effects of factors like prolonged exposure to potential risk factors, age-related physiological changes, and a diminished capacity for liver regeneration. Consequently, this demographic shift underscores the critical importance of comprehensive hepatological care and emphasizes the need for advanced diagnostic and therapeutic solutions tailored to the specific challenges faced by geriatric patients. However, the high cost associated with advanced treatments such as liver transplantation and specific pharmaceutical interventions poses a significant restraint in the hepatology market. These expenditures may create barriers to access for some patients and place substantial financial burdens on healthcare systems. Also, for individuals with end-stage liver disease, a liver transplant may represent their sole possible treatment option. Unfortunately, the demand for organs frequently surpasses the available supply, resulting in extended waiting lists and, regrettably, occasionally unfavorable outcomes for those in need of this life-saving procedure. This scarcity and prolonged wait times highlight a critical challenge in the field of hepatology, further hindering the target market.

By Treatment Type

  • Antiviral Drugs
  • Vaccines
  • Immunosuppressants
  • Targeted Therapy
  • Chemotherapy
  • Corticosteroids
  • Immunoglobulins

By Disease Type

  • Hepatitis
  • Liver Cancer
  • Genetic Disorders 
  • Autoimmune Diseases
  • Non- Alcoholic Fatty Liver Diseases 
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the increasing awareness about liver health, increasing prevalence of liver disorders, improved diagnostic methods, a rise in the aging population, increased R&D efforts, and the presence of a strong diagnosis system that maintains the accuracy of illness identification and treatment outcomes is anticipated to drive the market growth in North America. Moreover, available healthcare policies for treatments, along with healthcare insurance and government initiatives for better access to treatments in the region, accelerated the market’s expansion. Also, the strong pharmaceutical and biotechnology industries promise the innovation of novel therapeutic development for liver conditions, further boosting the market growth. Therefore, the above-mentioned factors are likely to propel the market growth over the forecast period in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Hepatology Market By Treatment Type, By Disease Type, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Hepatology Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Hepatology Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Hepatology Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Hepatology Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Antiviral Drugs
      2. Vaccines
      3. Immunosuppressants
      4. Targeted Therapy
      5. Chemotherapy
      6. Corticosteroids
      7. Immunoglobulins
  • 8.  Hepatology Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Hepatitis
      2. Liver Cancer
      3. Genetic Disorders 
      4. Autoimmune Diseases
      5. Non- Alcoholic Fatty Liver Diseases 
      6. Others
  • 9.  North America Hepatology Market Analysis 2017-2022and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.  Latin America Hepatology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.  Europe Hepatology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.  Asia Pacific Hepatology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031  

  • 13.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Astellas Pharma Inc.
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Merck & Co. Inc.
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Abbott Laboratories
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Bristol- Myers Squibb
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. AbbVie Inc.
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Emergent BioSolutions Inc.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. F. Hoffmann- La Roche AG
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Eli Lilly and Company
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Viatris Inc.
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Gilead Sciences, Inc.
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client
    •    

Partner

Our Clients